The XXVII Russian Oncology Congress, the largest national oncology event in Russia, took place in Moscow on November 14-16. The Congress is organized by the Russian Society of Clinical Oncology (RUSSCO) in cooperation with the N.N. Blokhin National Medical Research Center of Oncology and the Association of Oncologists of Russia. 

During the forum's plenary sessions, symposia, lectures, and master classes, more than 3,000 experts engaged in discussions on current topics in applied oncology. Leading Russian and international oncologists presented the main achievements in diagnostics and treatment of malignant tumors.

The Pharmasyntez Group of Companies presented its portfolio of antineoplastic agents at the exhibition of the Russian pharmaceutical industry leaders. Currently, it includes more than 45 drugs for the treatment of malignant neoplasms of various localizations. 

At Pharmasyntez-Nord site in St. Petersburg, the company produces effective and affordable drugs for chemotherapy, hormone, and targeted therapy. 99% of the drugs produced are included in the list of vital and essential drugs of the Russian Ministry of Health.